nitrendipine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium channel blockers, nifedipine derivatives 1947 39562-70-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nitrendipine
  • nitrendipin
  • nitrepin
A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
  • Molecular weight: 360.37
  • Formula: C18H20N2O6
  • CLOGP: 3.73
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 1
  • TPSA: 107.77
  • ALOGS: -4.41
  • ROTB: 7

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.92 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 16.50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 6.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 25 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1985 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
General physical health deterioration 80.24 37.14 58 2073 142376 50460617
Product prescribing error 76.86 37.14 30 2101 20931 50582062
Fall 75.76 37.14 81 2050 334851 50268142
Antinuclear antibody negative 74.26 37.14 12 2119 204 50602789
Coombs positive haemolytic anaemia 68.86 37.14 12 2119 327 50602666
Herpes simplex reactivation 66.97 37.14 12 2119 385 50602608
Gastritis haemorrhagic 52.43 37.14 12 2119 1325 50601668
Antiphospholipid syndrome 50.93 37.14 12 2119 1505 50601488
Complex regional pain syndrome 47.67 37.14 12 2119 1981 50601012
Hypertensive angiopathy 45.67 37.14 7 2124 83 50602910
Lymphopenia 45.64 37.14 19 2112 15602 50587391
Premature baby 42.71 37.14 19 2112 18318 50584675
Hypertension 40.48 37.14 47 2084 211156 50391837
Anxiety disorder 40.40 37.14 12 2119 3661 50599332
Hyperlipidaemia 40.34 37.14 18 2113 17472 50585521
Hypertensive crisis 38.42 37.14 16 2115 13138 50589855

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dizziness 64.52 30.82 79 2394 189605 29382449
Product prescribing error 64.50 30.82 31 2442 17945 29554109
Rectal prolapse 57.08 30.82 11 2462 260 29571794
Intraductal papillary mucinous neoplasm 54.59 30.82 11 2462 329 29571725
Vena cava injury 53.11 30.82 10 2463 208 29571846
Renal cyst haemorrhage 52.67 30.82 11 2462 394 29571660
SARS-CoV-2 antibody test positive 52.45 30.82 10 2463 223 29571831
Syncope 50.97 30.82 47 2426 81324 29490730
Spinal osteoarthritis 39.06 30.82 16 2457 6340 29565714
Carotid arteriosclerosis 38.82 30.82 11 2462 1427 29570627
Left ventricular hypertrophy 38.23 30.82 16 2457 6687 29565367
Tongue biting 35.98 30.82 9 2464 724 29571330
Delayed graft function 35.64 30.82 11 2462 1916 29570138
Postrenal failure 35.38 30.82 8 2465 417 29571637
Osteochondrosis 35.12 30.82 9 2464 798 29571256
Abdominal wall haemorrhage 33.56 30.82 7 2466 249 29571805
Mean cell volume increased 32.87 30.82 11 2462 2478 29569576
General physical health deterioration 31.85 30.82 41 2432 102816 29469238

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product prescribing error 142.76 32.48 61 4068 35208 64459395
General physical health deterioration 111.25 32.48 97 4032 204328 64290275
Dizziness 94.34 32.48 126 4003 430037 64064566
Syncope 90.11 32.48 77 4052 157558 64337045
Tongue biting 68.43 32.48 17 4112 1743 64492860
Fall 59.45 32.48 100 4029 416726 64077877
Vena cava injury 55.24 32.48 10 4119 220 64494383
SARS-CoV-2 antibody test positive 54.44 32.48 10 4119 239 64494364
Renal cyst haemorrhage 54.15 32.48 11 4118 451 64494152
Intraductal papillary mucinous neoplasm 51.34 32.48 11 4118 586 64494017
Bradycardia 50.30 32.48 49 4080 118170 64376433
Hypertensive angiopathy 41.52 32.48 7 4122 100 64494503
Rectal prolapse 39.73 32.48 11 4118 1715 64492888
Dysuria 38.01 32.48 27 4102 42030 64452573
Carotid arteriosclerosis 37.71 32.48 11 4118 2068 64492535
Benign prostatic hyperplasia 37.51 32.48 16 4113 9149 64485454
Left ventricular hypertrophy 36.95 32.48 16 4113 9490 64485113
Hypertensive crisis 35.20 32.48 19 4110 18229 64476374
Postrenal failure 35.11 32.48 8 4121 566 64494037
Delayed graft function 33.60 32.48 11 4118 3025 64491578

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C08CA08 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
Dihydropyridine derivatives
ATC C09BB06 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and calcium channel blockers
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35620 vasodilator agents
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:38215 calcium channel blockers
CHEBI has role CHEBI:176497 geroprotectors

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.37 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Voltage-dependent L-type calcium channel subunit alpha-1D Ion channel GATING INHIBITOR IC50 8.40 IUPHAR IUPHAR
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel BLOCKER Ki 9.60 CHEMBL SCIENTIFIC LITERATURE
Intermediate conductance calcium-activated potassium channel protein 4 Ion channel BLOCKER IC50 7.60 IUPHAR
Voltage-dependent calcium channel gamma-1 subunit Ion channel WOMBAT-PK
Transthyretin Secreted IC50 5.92 WOMBAT-PK
Cytochrome P450 2C9 Enzyme IC50 6.52 DRUG MATRIX
Voltage-dependent T-type calcium channel subunit alpha-1H Ion channel IC50 5.06 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1F Ion channel GATING INHIBITOR IC50 6 IUPHAR
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 4.44 CHEMBL
Cytochrome P450 2C19 Enzyme IC50 5.52 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.08 WOMBAT-PK
Adenosine receptor A1 GPCR Ki 5.05 CHEMBL
Adenosine receptor A2a GPCR Ki 4.64 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel GATING INHIBITOR IC50 6 IUPHAR
Voltage-dependent L-type calcium channel subunit alpha-1S Ion channel GATING INHIBITOR IC50 6 IUPHAR
Platelet-activating factor receptor GPCR Ki 4.13 CHEMBL

External reference:

IDSource
N0000167238 NUI
D00629 KEGG_DRUG
C0028127 UMLSCUI
CHEBI:7582 CHEBI
CHEMBL475534 ChEMBL_ID
CHEMBL251230 ChEMBL_ID
CHEMBL268609 ChEMBL_ID
DB01054 DRUGBANK_ID
D009568 MESH_DESCRIPTOR_UI
4507 PUBCHEM_CID
2334 IUPHAR_LIGAND_ID
4739 INN_ID
9B627AW319 UNII
7441 RXNORM
005383 NDDF
444757009 SNOMEDCT_US

Pharmaceutical products:

None